Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Capital Expenditures (2022 - 2025)

Axsome Therapeutics' Capital Expenditures history spans 4 years, with the latest figure at $71000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 136.67% year-over-year to $71000.0; the TTM value through Dec 2025 reached $480000.0, up 77.78%, while the annual FY2025 figure was $480000.0, 77.78% up from the prior year.
  • Capital Expenditures for Q4 2025 was $71000.0 at Axsome Therapeutics, up from $58000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $371000.0 in Q3 2023 and bottomed at $7000.0 in Q4 2023.
  • The 4-year median for Capital Expenditures is $80500.0 (2023), against an average of $127125.0.
  • The largest YoY upside for Capital Expenditures was 462.12% in 2023 against a maximum downside of 96.13% in 2023.
  • A 4-year view of Capital Expenditures shows it stood at $181000.0 in 2022, then plummeted by 96.13% to $7000.0 in 2023, then surged by 328.57% to $30000.0 in 2024, then surged by 136.67% to $71000.0 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Capital Expenditures are $71000.0 (Q4 2025), $58000.0 (Q3 2025), and $13000.0 (Q2 2025).